Press Releases Archives

QuartzBio SolveBio PR Social Image 20230123

QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development

Precision for Medicine, the first global, precision medicine, clinical research services organization today announced the strategic acquisition of SolveBio, which will now fall under the QuartzBio, part of Precision for Medicine brand and product portfolio. Read More →

Press Releases

Precision Medicine Group Secures Major Investment from Blackstone

New York, NY & Bethesda, MD -- November 20, 2020 -- Precision Medicine Group (PMG) and Blackstone (NYSE: BX) today announced that PMG, a leading next-generation provider of drug development and commercialization services, has completed a major investment and recapitalization led by funds managed by Blackstone (“Blackstone”). The investment includes significant participation from Precision’s co-founders, Ethan Leder and Mark Clein, as well as current shareholders Berkshire Partners, TPG Growth, Oak HC/FT, and Vida Ventures.

Press Releases

QuartzBio, part of Precision for Medicine, Expands Computational Biology and Launches Boston Office

July 16, 2019 — Boston, MA — QuartzBio, part of Precision for Medicine, today announced a significant expansion of its computational biology and multiomic data integration capabilities through the launch of a Boston-based office. The new office is one of many recent investments in Artificial Intelligence and computational biology expertise to cement its position as a leading solution for the integration, and analysis of biological data to support biomarker-guided drug development.

Press Releases

Precision for Medicine Acquires Industry-leading Artificial Intelligence Technology

March 6, 2019 — Bethesda, MD — Precision for Medicine, part of Precision Medicine Group, today announced the acquisition of SimplicityBio, adding artificial intelligence to Precision’s QuartzBio™ multiomic data integration and informatics platform. The addition of an artificial intelligence engine to QuartzBio provides Precision’s clients the most robust, sophisticated end-to-end solution for the “big data” challenge observed in biomarker-guided drug development—furthering their mission of maximizing the value and utility of biomarker data generated in the course of a clinical trial.